{"title":"氯胺酮诱导的小鼠行为紊乱、氧化还原失衡和神经递质缺陷:地奥米明作为抗精神病药的预防和逆转神经调节潜力","authors":"Aya-Ebi Okubo Eneni , Benneth Ben-Azu , Abayomi Mayowa Ajayi , Adegbuyi Oladele Aderibibge","doi":"10.1016/j.dscb.2025.100210","DOIUrl":null,"url":null,"abstract":"<div><div>Schizophrenia is a major neuropsychiatric disorder associated with neurochemical perturbations characterized by behavioral abnormalities, for which effective treatment remains elusive. The current study investigated the neurotransmitter modulatory effect of diosmin in preventing and reversing ketamine-induced neurochemical and oxidative perturbations in mice. In the preventive study, mice were first treated with diosmin (50 mg/kg, i.p.) or risperidone (0.5 mg/kg) for 14-days before ketamine (20 mg/kg, i.p.) administration from the 8th-14th day. However, in the reversal approach, mice were injected with ketamine (20 mg/kg, i.p.) for 14 days before treatment with diosmin (50 mg/kg, i.p.) or risperidone from days 8–14. Behavioral consequences were measured using open-field, Y-maze, forced-swim, and social interaction tests. Neurochemical and oxidative changes critical to the disease were characterized in the striatum, prefrontal cortex and hippocampus. Diosmin improved the behavioral abnormalities and improved memory in ketamine-treated mice. Also, diosmin prevented and reversed ketamine-induced oxidative stress, evidenced by increased glutathione and superoxide-dismutase with a profound decrease in malondialdehyde levels in the striatum, prefrontal-cortex and hippocampus. Additionally, diosmin reduced nitrite levels in the striatum in the preventive approach, but with a significant decrease in the striatum and prefrontal-cortex compared to ketamine groups. Ketamine-induced increased acetylcholinesterase activity in the hippocampus and prefrontal-cortex were both prevented and reversed significantly. Lastly, ketamine-induced dopamine, serotonin and glutamate dysregulations in the striatum, prefrontal-cortex and hippocampus were prevented and reversed by diosmin compared to ketamine controls. Conclusively, diosmin improved ketamine-induced neurobehavioral deficits by augmenting antioxidant systems and modulating neurotransmitters in mice brains.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"18 ","pages":"Article 100210"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ketamine-induced behavioral perturbations, redox imbalances, and neurotransmitter deficits in mice: The preventive and reversal neuromodulatory potential of diosmin as an antipsychotic\",\"authors\":\"Aya-Ebi Okubo Eneni , Benneth Ben-Azu , Abayomi Mayowa Ajayi , Adegbuyi Oladele Aderibibge\",\"doi\":\"10.1016/j.dscb.2025.100210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Schizophrenia is a major neuropsychiatric disorder associated with neurochemical perturbations characterized by behavioral abnormalities, for which effective treatment remains elusive. The current study investigated the neurotransmitter modulatory effect of diosmin in preventing and reversing ketamine-induced neurochemical and oxidative perturbations in mice. In the preventive study, mice were first treated with diosmin (50 mg/kg, i.p.) or risperidone (0.5 mg/kg) for 14-days before ketamine (20 mg/kg, i.p.) administration from the 8th-14th day. However, in the reversal approach, mice were injected with ketamine (20 mg/kg, i.p.) for 14 days before treatment with diosmin (50 mg/kg, i.p.) or risperidone from days 8–14. Behavioral consequences were measured using open-field, Y-maze, forced-swim, and social interaction tests. Neurochemical and oxidative changes critical to the disease were characterized in the striatum, prefrontal cortex and hippocampus. Diosmin improved the behavioral abnormalities and improved memory in ketamine-treated mice. Also, diosmin prevented and reversed ketamine-induced oxidative stress, evidenced by increased glutathione and superoxide-dismutase with a profound decrease in malondialdehyde levels in the striatum, prefrontal-cortex and hippocampus. Additionally, diosmin reduced nitrite levels in the striatum in the preventive approach, but with a significant decrease in the striatum and prefrontal-cortex compared to ketamine groups. Ketamine-induced increased acetylcholinesterase activity in the hippocampus and prefrontal-cortex were both prevented and reversed significantly. Lastly, ketamine-induced dopamine, serotonin and glutamate dysregulations in the striatum, prefrontal-cortex and hippocampus were prevented and reversed by diosmin compared to ketamine controls. Conclusively, diosmin improved ketamine-induced neurobehavioral deficits by augmenting antioxidant systems and modulating neurotransmitters in mice brains.</div></div>\",\"PeriodicalId\":72447,\"journal\":{\"name\":\"Brain disorders (Amsterdam, Netherlands)\",\"volume\":\"18 \",\"pages\":\"Article 100210\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain disorders (Amsterdam, Netherlands)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666459325000307\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain disorders (Amsterdam, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666459325000307","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ketamine-induced behavioral perturbations, redox imbalances, and neurotransmitter deficits in mice: The preventive and reversal neuromodulatory potential of diosmin as an antipsychotic
Schizophrenia is a major neuropsychiatric disorder associated with neurochemical perturbations characterized by behavioral abnormalities, for which effective treatment remains elusive. The current study investigated the neurotransmitter modulatory effect of diosmin in preventing and reversing ketamine-induced neurochemical and oxidative perturbations in mice. In the preventive study, mice were first treated with diosmin (50 mg/kg, i.p.) or risperidone (0.5 mg/kg) for 14-days before ketamine (20 mg/kg, i.p.) administration from the 8th-14th day. However, in the reversal approach, mice were injected with ketamine (20 mg/kg, i.p.) for 14 days before treatment with diosmin (50 mg/kg, i.p.) or risperidone from days 8–14. Behavioral consequences were measured using open-field, Y-maze, forced-swim, and social interaction tests. Neurochemical and oxidative changes critical to the disease were characterized in the striatum, prefrontal cortex and hippocampus. Diosmin improved the behavioral abnormalities and improved memory in ketamine-treated mice. Also, diosmin prevented and reversed ketamine-induced oxidative stress, evidenced by increased glutathione and superoxide-dismutase with a profound decrease in malondialdehyde levels in the striatum, prefrontal-cortex and hippocampus. Additionally, diosmin reduced nitrite levels in the striatum in the preventive approach, but with a significant decrease in the striatum and prefrontal-cortex compared to ketamine groups. Ketamine-induced increased acetylcholinesterase activity in the hippocampus and prefrontal-cortex were both prevented and reversed significantly. Lastly, ketamine-induced dopamine, serotonin and glutamate dysregulations in the striatum, prefrontal-cortex and hippocampus were prevented and reversed by diosmin compared to ketamine controls. Conclusively, diosmin improved ketamine-induced neurobehavioral deficits by augmenting antioxidant systems and modulating neurotransmitters in mice brains.